On Monday afternoon, Elan voluntarily withdrew its lawsuit filed a week ago in the U.S. District Court for the Southern District of New York to compel corrective disclosure in Royalty Pharma's tender offer documents

On Monday afternoon, Elan voluntarily withdrew its lawsuit filed a week ago in the U.S. District Court for the Southern District of New York to compel corrective disclosure in Royalty Pharma's tender offer documents

Synergy Pharmaceuticals Inc., of New York, appointed Patrick H. Griffin chief medical officer

Due to this considerable growth, the Nasdaq OMX Group Inc., of New York, said it is modifying the methodology used to arrive at a valuation for the Nasdaq Biotechnology Index (NBI

On Monday afternoon, Elan voluntarily withdrew its lawsuit filed a week ago in the U.S. District Court for the Southern District of New York to compel corrective disclosure in Royalty Pharma's tender offer documents

Stemline Therapeutics Inc., of New York, received orphan drug designation from the FDA for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic malignancy for which there is no effective treatment

Needham & Co. $182.7 $2.13B NPS Pharmaceuticals Inc. (Bedminster, N.J.; NPSP)20 8/3/11 5/20/13 6.9S $14.53 101.2 J.P. Morgan Securities Morgan Stanley (co-lead) Canaccord Genuity Leerink Swann $100.26 $1.5B Rockwell Medical Inc. (Wixom, Mich.; RMTI)21 6/13/12 5/15/13 13.2S $3.05 39.2 Chardan Capital Markets Summer Street Research C&Co./Princeridge $40.3 $119.56 Stemline Therapeutics Inc. (New York; STML)22 5/17/13 5/17/13 4.76 $14.50 12.28 Roth Capital Partners $69 $178.06 Total: $1,683

Charlottesville, Va.-based Biovista has collaborations with Pfizer Inc., of New York, and Novartis AG, of Basel, Switzerland, as well as the FDA's Office of Clinical Pharmacology. (See BioWorld Today, Nov. 10, 2010, and BioWorld Insight, Nov. 29, 2010.) In March, Cambridge, Mass.-based DART Therapeutics Inc

Pfizer Inc., of New York, began a Phase I trial of PF-06410293 (adalimumab), its biosimilar version of Humira

Aeterna Zentaris Inc., of Quebec City, said the class action lawsuit filed against the company and certain of its officers by Faruqi & Faruqi LLP in the U.S. District Court for the Southern District of New York has been entirely dismissed with prejudice and without leave to amend...Royalty Pharma, of New York, increased its hostile bid to acquire Elan Corp

Royalty Pharma, of New York, extended until June 21 the $6.4 billion offer to buy Elan Corp

New York-based Pfizer is responsible for development and commercializing PDCs, though the pair will work on preclinical research together...San Diego-based Ambrx Inc.'s site-specific ADC platform drew Bristol-Myers Squibb Co., of New York, for a third deal in May

BrainStorm Cell Therapeutics Inc., of New York, said it submitted a favorable safety report to the institutional review board for the first group of patients in its ongoing Phase IIa trial of NurOwn cells in amyotrophic lateral sclerosis (ALS) at the Hadassah Medical Center in Jerusalem

BrainStorm Cell Therapeutics Inc., of New York, received the third installment of a 2013 grant from Israel's Office of the Chief Scientist (OCS) for $335,000

Autifony Therapeutics Ltd., of London, said Pfizer Venture Investments, the venture capital arm of Pfizer Inc., of New York, invested £5 million (US$7.7 million) to join existing investors SV Life Sciences, Imperial Innovations plc and UCL Business plc in its Series A financing round

BrainStorm Cell Therapeutics Inc., of New York, received the third installment of a 2013 grant from Israel's Office of the Chief Scientist for $335,000...Elan Corp., of Dublin, Ireland, won a court injunction blocking Royalty Pharma Inc., of New York, from taking over Elan in a $6.4 billion hostile bid

Keryx Biopharmaceuticals Inc., of New York, presented updated efficacy and safety data from the Phase III long-term trial of Zerenex (ferric citrate), the company's ferric iron-based phosphate binder drug candidate for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis

Much of this year's ASCO chatter – at least in immunotherapeutics – centered on the investigational PD-1 compound nivolumab, from New York-based BMS, in combination with anti-CTLA-4 Yervoy in inoperable Stage III and Stage IV melanoma

AbbVie Inc., of Chicago, reported results from a Phase I study of ABT-199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and relapsed/refractory non-Hodgkin's lymphoma (NHL). The Phase I, open-label, multicenter, international trial was designed to assess the safety, determine the maximum tolerated dose and recommended Phase II dose, and evaluate the pharmacokinetics of ABT-199 in